[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644411":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":29,"centralContacts":46,"locations":53,"responsibleParty":70,"collaborators":29,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":74,"sex":80,"minAge":81,"maxAge":29,"enrollmentInfo":82,"targetDuration":29,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":95,"whyStopped":29,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Ottawa Hospital Research Institute","OTHER",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1","ACTIVE_COMPARATOR","1. Ondansetron 8mg taken twice daily by mouth for 5 days\n2. Aprepitant taken daily by mouth on the first (125mg), third (80mg), and fifth (80mg) day.\n3. Dexamethasone taken daily by mouth for 7 days (12mg on the first day, 8mg on subsequent days)\n4. Olanzapine 5mg taken at night by mouth for 7 days",[13,14,15,16],"Drug: Ondansetron (Control)","Drug: Aprepitant","Drug: Dexamethasone","Drug: Olanzapine",{"label":18,"type":19,"description":20,"interventionNames":21},"Group 2","EXPERIMENTAL","1. Netupitant\u002FPalonosetron\\* (300mg\u002F0.5mg) combination pill taken once daily by mouth on the first and third day of chemotherapy\n2. Dexamethasone 4mg taken once daily by mouth for 5 days\n3. Olanzapine 5mg taken at night by mouth for 7 days",[22,15,16],"Drug: Netupitant\u002FPalonosetron Hydrochloride",[24,30,34,38,42],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","Netupitant\u002FPalonosetron Hydrochloride","300mg\u002F0.5mg combination pill taken once daily by mouth on the first and third day of chemotherapy",[18],null,{"type":25,"name":31,"description":32,"armGroupLabels":33,"otherNames":29},"Ondansetron (Control)","8mg taken twice daily by mouth for 5 days",[9],{"type":25,"name":35,"description":36,"armGroupLabels":37,"otherNames":29},"Aprepitant","Daily by mouth on the first (125mg), third (80mg), and fifth (80mg) day",[9],{"type":25,"name":39,"description":40,"armGroupLabels":41,"otherNames":29},"Dexamethasone","Daily by mouth for 7 days (12mg on the first day, 8mg on subsequent days)",[9,18],{"type":25,"name":43,"description":44,"armGroupLabels":45,"otherNames":29},"Olanzapine","5mg taken at night by mouth for 7 days",[9,18],[47],{"name":48,"role":49,"phone":50,"phoneExt":51,"email":52},"Dominick Bossé, M.D.","CONTACT","1-613-737-7700","70166","dbosse@toh.ca",[54],{"facility":55,"status":29,"city":56,"state":57,"zip":58,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":67},"Ottawa Hospital Cancer Centre","Ottawa","Ontario","K1H 8L6","Canada","CA",{"type":62,"coordinates":63},"Point",[64,65],-75.69812,45.41117,{"lat":65,"lon":64},[68],{"name":69,"role":49,"phone":50,"phoneExt":51,"email":52},"Dominick Bossé, Medical Oncologist",{"type":71,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR","100644411","early-phase-1-a-simplified-regimen-to-prevent-nausea-and-vomiting-using-netupitantpalonosetron-in-germ-cell-cancer-patients-receiving-chemotherapy-100644411",false,"NCT07662200","A Simplified Regimen to Prevent Nausea and Vomiting Using Netupitant\u002FPalonosetron in Germ Cell Cancer Patients Receiving Chemotherapy","A Pilot Feasibility Study of a Steroid-Sparing Anti-Nausea and Vomiting Regimen With Netupitant\u002FPalonosetron for Patients With Germ Cell Tumours Receiving Multi-Day Cisplatin-Based Chemotherapy at The Ottawa Hospital","SPARROW-GC","1. Diagnosis of germ cell cancer\n2. Indication for outpatient treatment using a standard 5-day cisplatin-based chemotherapy regimen","ALL","18 Years",{"count":83,"type":84},10,"ESTIMATED","INTERVENTIONAL",[87],"EARLY_PHASE1","This is a single-site, open-label, randomized pilot feasibility study conducted at The Ottawa Hospital Cancer Centre. A total of 10 participants will be randomized 1:1 to either the experimental or control arm.\n\nThe purpose of this study is to evaluate recruitment capability, intervention adherence, data completeness, and safety prior to consideration of a potential future multi-centre randomized trial.",[90],"Germ Cell Cancer",[78,92,93,94],"Netupitant","Palonosetron","Steroid-Sparing Anti-Nausea and Vomiting Regimen","NOT_YET_RECRUITING","2026-06-18",{"date":98,"type":99},"2026-06-23","ACTUAL",{"date":101,"type":84},"2026-08",{"date":103,"type":84},"2028-08",{"name":5,"class":6},1]